



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, DC 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/480,850	06/07/95	PELLETT	P 1414.657

JAMIE L. GREENE  
JONES AND ASKEW  
37TH FLOOR  
191 PEACHTREE STREET  
ATLANTA GA 30303

18M1/0528

EXAMINER

LEE, D

ART UNIT	PAPER NUMBER
1815	

DATE MAILED: 05/28/97

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

## Office Action Summary

Application No. <b>08/480,850</b>	Applicant(s) <b>Philip E. Pellett</b>
Examiner <b>Danny Lee</b>	Group Art Unit <b>1815</b>



Responsive to communication(s) filed on May 14, 1997.

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

### Disposition of Claims

Claim(s) 7, 8, and 16 is/are pending in the application.

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

Claim(s) \_\_\_\_\_ is/are allowed.

Claim(s) 7, 8, and 16 is/are rejected.

Claim(s) \_\_\_\_\_ is/are objected to.

Claims \_\_\_\_\_ are subject to restriction or election requirement.

### Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

The proposed drawing correction, filed on \_\_\_\_\_ is  approved  disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All  Some\*  None of the CERTIFIED copies of the priority documents have been received.

received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_.

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

### Attachment(s)

- Notice of References Cited, PTO-892
- Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_
- Interview Summary, PTO-413
- Notice of Draftsperson's Patent Drawing Review, PTO-948
- Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

**DETAILED ACTION**

1. Receipt is acknowledged of applicants' amendment after final in Paper No. 14, filed 5/14/97, wherein claims 7-8, 16 are amended and no new claims are presented. Accordingly, claims 7-8, 16 are under consideration in the present application.
  
2. Rejection of claims 7-8 and 16 under 35 U.S.C. 102(b) as anticipated or 35 U.S.C. 103 as being obvious over either Lee et al. (Applicant's AA1) or Lee et al. (Applicant's AW) is **withdrawn**.
  
3. Rejection of claims 7-8 and claim 16 under 35 U.S.C. § 103 as being unpatentable over Lee et al. (AA1) or Lee et al. (AW) in view of Luckow et al. (AO) or Matsuura et al. (AP) is **maintained and made final** for the reasons of record because applicant fails to put the claims in condition for allowance and the claims has not been amended to warrant new grounds of rejection, the modifications of 'pure' to 'recombinant' in claims 7-8 do not alter the scope thus the claims.

Applicant's arguments filed 5/14/97 (paper No. 14) have been considered are not deemed persuasive. Applicant argues that the novel plasmid pAcDSM, is engineered to receive the foreign gene precisely at the translation initiation codon of the polyhedron gene, without missing any nucleotide present in the native 5' nontranslated leader sequence is noted, but these limitations are not in the claims. **The claims are drawn to a purified herpes simplex virus gG1 and/or gG-2 antigens and not toward the baculoviral expression system.** Applicant's claims constitute a

product-by-process type claims and the burden is upon applicant to demonstrate the distinction between the material, structural and functional characteristics of the claimed composition and the compositions of the prior art. Applicant argues that the protein made by the expression system of Sanchez-Martinez and Pellett, may differ from the art because of the differences of the transfer vector.

Lee et al (1985) and Lee et al (1986) teach purified natural HSV glycoprotein gG-1 and gG-2.

*Luckow et al. discloses the development of baculovirus expressions systems and the advantages of using such systems for "the very abundant expression of recombinant proteins, which are in many cases, antigenically, immunologically, and functionally similar to their authentic counterparts" (see page 47, first column, first full paragraph). Neither Luckow et al. or Matsuura et al. teach the expression of gG-1 or gG-2 peptides in baculovirus expression systems. However, the level of ordinary skill in the genetic engineering art is exceptionally high and, absent convincing objective evidence to the contrary, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to express the gG-2 protein of Lee et al. (AA1) or the gG-1 protein of Lee et al. (AW) in the baculovirus expression system of Luckow et al. or Matsuura et al. for the expected benefit of obtaining high levels of expression of gG-1 and gG-2 proteins suitable for use as diagnostic or immunological reagents. One of ordinary skill in the art would have been motivated to express the proteins in a baculovirus system since Luckow et al. and Matsuura et al. disclose the numerous advantages of baculovirus expressions systems and one of ordinary skill would have had a reasonable expectation of success since Luckow et al. and Matsuura et al. both establish that the baculovirus system produces significant amounts of peptides and that such peptides "are in many cases, antigenically, immunologically, and functionally similar to their authentic counterparts." More ever, the selection of a particular transfer vector is deemed to be a result-effective parameter routinely optimized by the artisan of ordinary skill as taught by Matsuura and Luckow.*

*Luckow et al. also discloses many of the vectors suitable for baculovirus expression systems and the importance of particular leader sequences upstream from the polyhedron gene ATG and their impact on protein production (see page 51, first column, last paragraph). Similarly, Matsuura et al. also discloses the uses and advantages of the baculovirus expression system and teaches "that the immediate 5' upstream sequences are important for high level expression" (see page 1234, Figure 1 and see page 1247, second full paragraph).*

Thus, the transfer vector disclosed in the specification is deemed obvious under 35 U.S.C. §103.

In conclusion, applicants (product-by-process) recombinant proteins is made obvious by the Lee et al (1985), Lee et al (1986), Matsuura and Luckow. Applicant has failed to provide convincing evidence and arguments to support a patentable distinction between the proteins of the prior art and those claimed by applicants. **Applicant is requested to submit evidence to show the distinction of the claimd gG1 and gG2 proteins and those of the prior art. How is the baculoviral vector of the instant invention contribute to unobvious distinction of the glycoprotein over the glycoprotein of the prior art (both Lee et al in view of Matsuura)?, How is the glycosylation pattern altered? , How is the methylation pattern?, post translational modification of the gG proteins and its eventual effect on the antigenicity the the glycoprotein or its immune and/or diagnostic alteration that will allow it to be better recognized over the glycoprotein of the prior art.**

No claims are allowed.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for response to this final action is set to expire THREE MONTHS from the date of this action. In the event a first response is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for response expire later than SIX MONTHS from the date of this final action.

Papers relating to this application may be submitted to Group 1800 by facsimile transmission. Papers should be faxed to Group 1800 located in Crystal Mall 1. The Fax number for Art Unit 1813 is (703) 305-7939. All Group 1800 Fax machines will be available to receive transmissions 24 hrs/day, 7 days/wk. Please note that the faxing of such papers must conform with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Danny Lee whose telephone number is (703) 305-7245. The

Serial Number: 08/480,850  
Art Unit: 1815  
Examiner: Danny Lee

---

Page 6

Examiner can normally be reached on Monday-Tuesday from 8:00 AM-6:30 PM, (EST)and Thursday-Friday from 8:00 AM-6:30 PM (EST).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Marian Knode, can be reached at (703) 308-4311.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Danny Lee

May 26, 1997

*Marian C. Knode*

MARIAN C. KNODE  
SUPERVISORY PATENT EXAMINER  
GROUP 1800